Further increase in earnings and equity
|
EQS-News: MPH Health Care AG
/ Key word(s): Annual Report/Dividend
MPH Health Care AG publishes Annual Report 2024:
Berlin, 28 May 2025 - MPH Health Care AG (ISIN: DE000A289V03) today published its Annual Report for 2024. In the 2024 financial year, the company once again benefited from the good performance of its investments and achieved a net profit for the year according to IFRS of EUR 32.0 million (prev. year: EUR 29.5 million). The operating result (EBIT) rose from EUR 30.2 million to EUR 33.0 million and equity increased by EUR 26.9 million from EUR 251.0 million to EUR 277.9 million. The net asset value (NAV) per share rose to EUR 64.90 as of 31 December 2024 (prev. year: EUR 58.62). With the dividend proposal of EUR 1.20 per share, the Executive Board and Supervisory Board are reaffirming the company's dividend policy. MPH AG is an investment company whose investments are recognised as financial assets under the balance sheet item "Financial assets" and are measured at fair value through profit or loss as at the balance sheet date. The net profit for the year is mainly the result of the fair value measurement of the listed investments held as at the balance sheet date, resulting from the higher market prices of the investments compared to the previous year's balance sheet date. The MPH Health Care AG Annual Report 2024 is available for download at www.mph-ag.de. About MPH Health Care AG: MPH Health Care AG is an investment company with a strategic focus on the acquisition, development and sale of companies and company shares, particularly in growth segments of the healthcare market. This includes both insurance-financed and privately financed segments. However, MPH also utilises the potential offered by high-growth and profitable sectors outside the healthcare market. Contact:Patrick Brenske, Management Board Corporate Communications E-Mail: ir@mph-ag.de
28.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | MPH Health Care AG |
| Grünauer Straße 5 | |
| 12557 Berlin | |
| Germany | |
| Phone: | 030 / 863 21 45 60 |
| Fax: | 030 / 863 21 45 69 |
| E-mail: | info@mph-ag.de |
| Internet: | www.mph-ag.de |
| ISIN: | DE000A289V03, DE000A289VT5 |
| WKN: | A289V0 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2146484 |
| End of News | EQS News Service |
|
|
2146484 28.05.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.